Pacira Pharma (PCRX) Misses Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Pacira BioSciences Reports Full-Year and Fourth Quarter 2022 Financial Results
February 28, 2023 8:00 AM ESTRecord revenues of $667 million in 2022
Full-year GAAP net income of $16 million and adjusted EBITDA of $213 million
EXPAREL surpasses the 12 million patient mark
Conference call today at 8:30 a.m. ET
TAMPA, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the fourth quarter and full-year of 2022.
2022 was a solid year for Pacira as we posted record revenue and significant... More
